The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes

Rhea-AI Summary

The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the US, will be added to both the Russell 2000® and Russell 3000® indexes following the 2025 annual reconstitution, effective June 27. The inclusion is based on TOI's market capitalization ranking among the 4,000 largest US stocks as of April 30. This milestone reflects TOI's growth and market presence in value-based cancer care. The Russell indexes, which benchmark approximately $10.6 trillion in assets, are widely used by investment managers and institutional investors for index funds and active investment strategies. CEO Daniel Virnich emphasized that this inclusion demonstrates TOI's successful execution and innovative approach to cancer care, while reinforcing their commitment to patient outcomes and shareholder value.

Positive

• Inclusion in widely-tracked Russell 2000® and Russell 3000® indexes increases visibility to institutional investors
• Potential for increased trading volume and liquidity due to index fund purchases
• Recognition of company's market capitalization growth and expansion

Negative

• None.

Insights

Investment Strategist

TOI's inclusion in Russell indexes increases visibility and potential investment from index funds tracking $10.6 trillion in assets.

The Oncology Institute's inclusion in the Russell 2000® and Russell 3000® Indexes represents a significant milestone for the company that extends beyond mere prestige. This development, effective June 27, positions TOI within indexes that serve as benchmarks for approximately $10.6 trillion in assets, potentially expanding the company's investor base substantially.

Index inclusion typically triggers mandatory buying from passive funds that track these indexes, potentially providing near-term support for the stock. More importantly, this inclusion grants TOI greater visibility among institutional investors who use these benchmarks for performance comparison. For a value-based oncology group, this institutional recognition validates their business model in the competitive healthcare sector.

The Russell 2000® specifically tracks small-cap companies, while inclusion in the broader Russell 3000® provides exposure to both small and large-cap focused investment vehicles. TOI's simultaneous addition to both indexes optimizes their visibility across different investor categories.

For shareholders, this development may translate to improved trading liquidity and potentially reduced volatility over time. The inclusion also subjects TOI to greater institutional scrutiny, which typically drives higher standards of corporate governance and transparency - beneficial for long-term investors focused on the company's value-based oncology care model and market expansion strategy.

CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index and the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“We are thrilled to be included in the Russell Indexes, which marks a significant milestone in TOI’s growth journey,” said Daniel Virnich, CEO of TOI. “This inclusion reflects our continued execution and the impact of our innovative, value-based approach to cancer care. As we continue to expand our presence across markets, we remain focused on improving outcomes for patients and creating long-term value for our shareholders.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.

For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better.

For more information, visit www.theoncologyinstitute.com

Contacts

Media

The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors

Solebury Strategic Communications
investors@theoncologyinstitute.com

FAQ

What does TOI's inclusion in the Russell indexes mean for investors?

The inclusion means automatic investment from index funds tracking these benchmarks, potentially increasing trading volume and visibility to institutional investors. About $10.6 trillion in assets are benchmarked against Russell US indexes.

When will TOI be added to the Russell 2000 and Russell 3000 indexes?

TOI will be added to both indexes after the US market closes on June 27, 2025, as part of the annual Russell indexes reconstitution.

How are companies selected for the Russell indexes?

Companies are selected based on their market capitalization ranking among the 4,000 largest US stocks as of April 30, along with other objective criteria and style attributes determined by FTSE Russell.

What is The Oncology Institute's (TOI) main business focus?

TOI is one of the largest value-based oncology groups in the United States, focused on providing innovative cancer care while improving patient outcomes.

How long will TOI remain in the Russell indexes?

Membership in the Russell 3000® Index remains in place for one year, with annual reconstitution determining continued inclusion based on market capitalization rankings.